Ani Pharmaceuticals Stock News

Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ: IDYA ) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi Trends (NASDAQ: CTRN ) is projected to report quarterly earnings at $1.12 per share on revenue of $250.54 million. • Precision BioSciences (NASDAQ: DTIL ) is likely to report quarterly loss at $0.47 per share on revenue of $7.75 million. • SPX FLOW (NYSE: FLOW ) is estimated to report quarterly loss at $0.17 per share on revenue of $10.88 million. • Brickell Biotech (NASDAQ: BBI ) is likely to report quarterly loss at $0.08 per share on revenue of $150.00 thousand. • Imara (NASDAQ: IMRA ) is expected to report earnings for its fourth quarter. • Gamida Cell (NASDAQ: GMDA ) is estimated to report earnings for its fourth quarter. • Syros Pharmaceuticals (NASDAQ: SYRS ) is likely to report quarterly loss at $0.47 per share on revenue of $4.80 million. • Global X Guru Index ETF (NYSE: GURU ) is likely to report quarterly loss at $0.

ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open.The consensus EPS Estimate is $0.74 (-7.5% Y/Y) and the…

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2021 financia

Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BioMarin (BMRN) delivered earnings and revenue surprises of 250% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Related Stocks: ASLN , ANIP , ALLK , IMGN , BLU , LEGN , BCAB , APVO , NXTC ,

Today, we revisit specialty pharmaceutical concern ANI Pharmaceuticals for the first time since spring. The company has seen some positive news flow since we last revisited, but the shares of this GAR

The Federal Trade Commission has issued a final order that clears the way for ANI Pharmaceuticals'' $210M acquisition of privately held Novitium Pharma

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer

SRTS, ANIP, and AZO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2022

SRTS, ANIP, and AZO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2022

New York State Teachers Retirement System lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,780 shares of the specialty pharmaceutical companys stock after selling 400 shares during the quarter. []

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients Show Lackluster Efficacy CytomX

Key Players covered in the Cancer Cachexia Market Research Report are Bristol-Myers Squibb Company, New York, U.S., ANI Pharmaceuticals, Inc., Baudette, U.S., Merck & Co., Inc., Kenilworth, U.S., Hikma Pharmaceuticals PLC, London, U.K., Mylan N.V., Pennsylvania, U.S., AbbVie, Inc., North Chicago, U.S., Pfizer Inc., New York, U.S., Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel and others. Key Players covered in the Cancer Cachexia Market Research Report are Bristol-Myers Squibb Company, New York, U.S., ANI Pharmaceuticals, Inc., Baudette, U.S., Merck & Co., Inc., Kenilworth, U.S., Hikma Pharmaceuticals PLC, London, U.K., Mylan N.V., Pennsylvania, U.S., AbbVie, Inc., North Chicago, U.S., Pfizer Inc., New York, U.S., Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel and others.